{"id":272,"date":"2008-12-01T10:19:47","date_gmt":"2008-12-01T18:19:47","guid":{"rendered":"https:\/\/derm-biomepharmaceuticals.com\/?p=272"},"modified":"2019-02-11T10:22:10","modified_gmt":"2019-02-11T18:22:10","slug":"novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio","status":"publish","type":"post","link":"https:\/\/derm-biomepharmaceuticals.com\/ch\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/","title":{"rendered":"Novelix Pharmaceuticals, Inc. \u542f\u52a8\u57fa\u4e8e NVX-207 \u5c40\u90e8\u4f7f\u7528\u7684\u5149\u5316\u6027\u89d2\u5316\u75c5\u836f\u7269\u5f00\u53d1\u8ba1\u5212\u5e76\u6269\u5927\u77e5\u8bc6\u4ea7\u6743\u7ec4\u5408"},"content":{"rendered":"<p>[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text]<\/p>\n<h4>2008 \u5e74 12 \u6708 1 \u65e5<\/h4>\n<p>LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211;Novelix Pharmaceuticals, Inc. (Novelix), a biopharmaceutical company developing small molecule cancer therapeutics, announced today that it has selected the large-market indication of actinic keratosis (AK) as the main focus of the company\u2019s dermatology development program. NVX-207, a targeted therapeutic regulating caspase-9, has shown itself to be ideally suited for topical treatment. Strong patents covering the composition of the drug candidate issued recently in the US and China. Over 30 European countries are expected to issue additional patents in January 2009.[\/vc_column_text][vc_empty_space][button size=&#8221;large&#8221; target=&#8221;_blank&#8221; hover_type=&#8221;default&#8221; text=&#8221;Read Article&#8221; link=&#8221;https:\/\/www.businesswire.com\/news\/home\/20081201006193\/en\/Novelix-Pharmaceuticals-Initiates-Actinic-Keratosis-Drug-Development&#8221;][vc_separator type=&#8221;normal&#8221; color=&#8221;#cccccc&#8221; thickness=&#8221;1&#8243; up=&#8221;50&#8243; down=&#8221;50&#8243;][\/vc_column][\/vc_row]<\/p>","protected":false},"excerpt":{"rendered":"<p>[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] December 1, 2008 LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211;Novelix Pharmaceuticals, Inc. (Novelix), a biopharmaceutical company developing small molecule cancer therapeutics, announced today that it has selected the large-market indication of actinic keratosis (AK) as the main focus of the company\u2019s dermatology development program. NVX-207, a targeted therapeutic regulating caspase-9, [&hellip;]<\/p>","protected":false},"author":2,"featured_media":270,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-272","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio - Derm-Biome Pharmaceuticals Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/derm-biomepharmaceuticals.com\/ch\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio - Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] December 1, 2008 LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211;Novelix Pharmaceuticals, Inc. (Novelix), a biopharmaceutical company developing small molecule cancer therapeutics, announced today that it has selected the large-market indication of actinic keratosis (AK) as the main focus of the company\u2019s dermatology development program. NVX-207, a targeted therapeutic regulating caspase-9, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/derm-biomepharmaceuticals.com\/ch\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2008-12-01T18:19:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-11T18:22:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"539\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Derm-Biome Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Derm-Biome Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/\"},\"author\":{\"name\":\"Derm-Biome Admin\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\"},\"headline\":\"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio\",\"datePublished\":\"2008-12-01T18:19:47+00:00\",\"dateModified\":\"2019-02-11T18:22:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/\"},\"wordCount\":179,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/\",\"name\":\"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio - Derm-Biome Pharmaceuticals Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg\",\"datePublished\":\"2008-12-01T18:19:47+00:00\",\"dateModified\":\"2019-02-11T18:22:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#primaryimage\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg\",\"width\":1000,\"height\":539},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/derm-biomepharmaceuticals.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"name\":\"Derm-Biome Pharmaceuticals Inc.\",\"description\":\"Startup Biopharmaceutical Company\",\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\",\"name\":\"Derm-Biome Pharmaceuticals\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"width\":450,\"height\":200,\"caption\":\"Derm-Biome Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\",\"name\":\"Derm-Biome Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"caption\":\"Derm-Biome Admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio - Derm-Biome Pharmaceuticals Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/derm-biomepharmaceuticals.com\/ch\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/","og_locale":"zh_CN","og_type":"article","og_title":"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio - Derm-Biome Pharmaceuticals Inc.","og_description":"[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] December 1, 2008 LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211;Novelix Pharmaceuticals, Inc. (Novelix), a biopharmaceutical company developing small molecule cancer therapeutics, announced today that it has selected the large-market indication of actinic keratosis (AK) as the main focus of the company\u2019s dermatology development program. NVX-207, a targeted therapeutic regulating caspase-9, [&hellip;]","og_url":"https:\/\/derm-biomepharmaceuticals.com\/ch\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/","og_site_name":"Derm-Biome Pharmaceuticals Inc.","article_published_time":"2008-12-01T18:19:47+00:00","article_modified_time":"2019-02-11T18:22:10+00:00","og_image":[{"width":1000,"height":539,"url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg","type":"image\/jpeg"}],"author":"Derm-Biome Admin","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"Derm-Biome Admin","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#article","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/"},"author":{"name":"Derm-Biome Admin","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d"},"headline":"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio","datePublished":"2008-12-01T18:19:47+00:00","dateModified":"2019-02-11T18:22:10+00:00","mainEntityOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/"},"wordCount":179,"commentCount":0,"publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg","articleSection":["Recent News"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/","url":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/","name":"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio - Derm-Biome Pharmaceuticals Inc.","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg","datePublished":"2008-12-01T18:19:47+00:00","dateModified":"2019-02-11T18:22:10+00:00","breadcrumb":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#primaryimage","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/02\/Novelix.jpg","width":1000,"height":539},{"@type":"BreadcrumbList","@id":"https:\/\/derm-biomepharmaceuticals.com\/novelix-pharmaceuticals-inc-initiates-actinic-keratosis-drug-development-program-based-on-topical-use-of-nvx-207-and-expands-intellectual-property-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/derm-biomepharmaceuticals.com\/"},{"@type":"ListItem","position":2,"name":"Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/derm-biomepharmaceuticals.com\/#website","url":"https:\/\/derm-biomepharmaceuticals.com\/","name":"Derm-Biome Pharmaceuticals Inc.","description":"Startup Biopharmaceutical Company","publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization","name":"Derm-Biome Pharmaceuticals","url":"https:\/\/derm-biomepharmaceuticals.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","width":450,"height":200,"caption":"Derm-Biome Pharmaceuticals"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d","name":"Derm-Biome Admin","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","caption":"Derm-Biome Admin"}}]}},"_links":{"self":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/posts\/272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/comments?post=272"}],"version-history":[{"count":1,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/posts\/272\/revisions"}],"predecessor-version":[{"id":273,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/posts\/272\/revisions\/273"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/media\/270"}],"wp:attachment":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/media?parent=272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/categories?post=272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/tags?post=272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}